Engineers Gate Manager LP increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4,309.4% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 15,918 shares of the biopharmaceutical company’s stock after buying an additional 15,557 shares during the quarter. Engineers Gate Manager LP’s holdings in Regeneron Pharmaceuticals were worth $9,926,000 at the end of the most recent reporting period.
A number of other hedge funds have also bought and sold shares of the business. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $26,000. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $26,000. Titan Wealth CI Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Trust Co. of Vermont purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Stock Performance
Shares of REGN opened at $793.26 on Friday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $752.38 and a two-hundred day simple moving average of $720.15. The stock has a market cap of $81.67 billion, a price-to-earnings ratio of 19.61, a PEG ratio of 1.58 and a beta of 0.20. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $859.34.
Regeneron Pharmaceuticals Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.
Key Regeneron Pharmaceuticals News
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: HSBC raised its price target to $920 from $800 and maintained a Buy rating, implying additional upside based on the firm’s assessment of Regeneron’s prospects. HSBC price-target report
- Neutral Sentiment: A Wells Fargo healthcare-conference presentation and transcript offered investors additional management commentary, though the provided report does not identify a specific new catalyst. Wells Fargo healthcare conference transcript
- Neutral Sentiment: A report showing zero short interest is likely incomplete or erroneous, because it also reports a zero-day short-interest ratio and an undefined percentage change; it provides little actionable information for investors.
- Negative Sentiment: Several law firms repeated notices about a securities class action against Regeneron, with a September 14, 2026 lead-plaintiff deadline. The lawsuit concerns alleged failures to disclose risks surrounding the Phase 3 Fianlimab-Libtayo trial for melanoma, including statistical and protocol issues and possible effects of FDA Optimus-related amendments on progression-free-survival analysis. The allegations have not been proven. REGN class-action deadline notice
- Negative Sentiment: Reports that American Century Investments sold Regeneron shares may add to concerns about institutional conviction, although the available coverage does not provide the size or timing of the sale. American Century Investments sale report
Insider Activity
In related news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the sale, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. The trade was a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald raised their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Leerink Partners increased their price target on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. Royal Bank Of Canada raised their price target on Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Canaccord Genuity Group cut their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Finally, Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Fourteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $802.18.
Read Our Latest Research Report on Regeneron Pharmaceuticals
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.
Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.
Read More
- Five stocks we like better than Regeneron Pharmaceuticals
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
